You are here

Drug Discovery


Today, scientists still do not know the cause of Alzheimer’s disease (AD), yet decades of research advancements give hope to the possibility of slowing down early-onset of AD. Benfotiamine, a therapeutic drug that raises blood vitamin B1, levels very high, was recently tested as a pilot clinical study conducted by the Gibson Lab at the Burke Neurological Institute.
Gibson Team in the Lab
In the Media
Media Outlet: 
CNN Health
Benfotiamine and Cognitive Decline in Alzheimer's Disease, a small exploratory clinical trial, conducted by Dr. Gary E. Gibson’s laboratory at the Burke Neurological Institute is listed in CNN Health’s article on ”Top 2020 health stories you may have missed because of Covid-19” under Advances in Alzheimer’s.
Gibson Team in the Lab
A small exploratory clinical trial conducted by Dr. Gary E. Gibson’s laboratory at the Burke Neurological Institute in collaboration with physicians at the Burke Rehabilitation Hospital, suggests that Benfotiamine is safe and potentially efficacious in improving cognitive outcomes among people living with Mild Cognitive Impairment and mild Alzheimer’s disease (AD).
Photo of Gibson Lab
Orjon Rroji, Amit Kumar, Saravanan S Karuppagounder, Rajiv R Ratan
Neurobiol Dis . 2020 Oct 27;105145. doi: 10.1016/j.nbd.2020.105145. Online ahead of print.
Abstract on PubMed
Gary E Gibson, José A Luchsinger, Rosanna Cirio, Huanlian Chen, Jessica Franchino-Elder, Joseph A Hirsch, Lucien Bettendorff, Zhengming Chen, Sarah Flowers, Linda Gerber, Thomas Grandville, Nicole Schupf, Hui Xu, Yaakov Stern, Christian Habeck, Barry Jordan, Pasquale Fonzetti
J Alzheimers Dis . 2020 Oct 16. doi: 10.3233/JAD-200896. Online ahead of print.
Abstract on PubMed
Journal Article
Yujia Zhai, Yingxin Chen, Saravanan S. Karuppagounder, Amit Kumar, Nandini Kundu, Ishraq Alim, Stephanie Taylor, Craig E. Brown, Xiang Luo, Yi-Fang Li, Dawei Lian, Yang Chen, Hilda Ahnstedt, Louise D. McCullough, Rong-Rong He, Rajiv R. Ratan
Conditioning Medicine 2020. 3(1): 1-8.
Full-Text on Conditioning Medicine
Journal Article
Aimé P, Karuppagounder SS, Rao A, Chen Y, Burke RE, Ratan RR, Greene LA.
Neurobiol Dis. 2020 Mar;136:104725. doi: 10.1016/j.nbd.2019.104725. Epub 2020 Jan 3.
Full-Text on Pubmed
Professors of Weill Cornell Medicine, the Burke Neurological Institute, and the Feil Family Brain and Mind Research Institute, have been awarded a grant from the National Institutes of Health (NIH) for a project to develop a non-opioid, non-addicting medicine for a hard-to-treat form of pain called neuropathic pain.
Photo of Dianna E. Willis, Ph.D., as Director of Research for the Burke-Blythedale Pediatric Neuroscience Research Collaboration
September 30, 2019 to July 31, 2021
Funding Status: 
Active Project
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Grant Number: 
Principal Investigator
When you first meet Jamie Petrone, it is impossible not to notice her engaging smile and friendly personality. The 42-year-old has an optimistic outlook on life which is a bit surprising given her diagnosis of transverse myelopathy (TM), a type of spinal cord injury that has caused her to use a wheelchair for much of her life.
Jamie walking with EKSO robot